Health Research Methods, Evidence, and Impact

Louise Bordeleau


Associate Professor, Department of Oncology

Associate Member, Dept of Health Research Methods, Evidence, and Impact

Working Group in Economic Analysis at the national Cancer Institute of Canada Clinical Trials Group (liaison for the Breast Site Group)
Breast Disease Site Executive Committee at the national Cancer Institute of Canada Clinical Trials Group
Member of the Hereditary Breast and Ovarian Cancer Clinical Study Group Ontario
Member of the Pan-Canadian Oncology Drug Review (Pcodr) Breast Cancer Clinical Guidance Panel
Member of the Pan-Canadian Oncology Drug Review (Pcodr) Economic Guidance Panel

905-387-9711 x64609

Juravinski Cancer Centre
3rd Floor Room 3-17
699 Concession Street
Hamilton Ontario, L8V 5C2

Administrative Assistant: Marcela Moyano
905-387-9711 x 64609

Academic Interests

Dr. Louise Bordeleau’s academic interests include 1) the study of breast cancer treatment and prevention through the participation of clinical trials, 2) the study of quality of life and survivorship issues related to breast cancer, 3) multifaceted collaborative work relating to women at high risk of breast cancer such as a) decision making re risk management, b) molecular profiling c) evaluation of novel screening (molecular imaging) and pre-screening technique (optical breast spectroscopy) d) establishment of a girl cohort in breast cancer families, e) psychosocial health care of patients and families obtaining genetic services, f) development and evaluation of a family disclosure decision aid for Hereditary Breast/Ovarian mutation carriers, g) the study of predictive testing attitudes in BRCA kindreds, 4) the relationship of cancer to diabetes and its treatment.

Selected Publications

  1. Lemieux J, Beaton DE, Hogg-Johnson S, Bordeleau LJ, Goodwin PJ. Three methods for minimally important difference: no relationship with the net proportion of patients improving.
                J Clin Epidemiol, 2007, 60(5):448-455.
  2. Lemieux J, Beaton D, Hogg-Johnson S, Bordeleau L, Hunter J, Goodwin P. Responsiveness to change to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer. Qual Life Res. 2007, 16(6):1007-1017.
  3. Lemieux J, Goodwin PJ, Pritchard KI, Gelmon KA, Bordeleau LJ, Duchesne T, Camden S, Speers C. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. Journal of Clinical Oncology, 2008, 26(27):4458-4465. 
  4. Panchal S, Ennis M, Canon S, Bordeleau LJ. Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Medical Genetics, 2008, 9: 116-125. [weight 0.50]
  5. Bordeleau LJ, Panchal S, Goodwin P.  Prognosis of BRCA associated breast cancer: A summary of evidence. Breast cancer research and Treatment, 2010, 119:13-24           
  6. Panchal S, Bordeleau L, Poll A, Llacuachaqui M, Shachar O, Ainsworth P, Armel S, Eisen A, Sun P, Narod S. Does family history predict the age-at-onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clinical Genetic, 2010, 77(3):273-279.
  7. Tsoi DT, Holloway CMB, Bordeleau L, Brezden-Masley CB, Warner E.  Willingness of Breast Cancer Survivors to Participate in a Randomized Controlled Trial of Digital Mammography with or without MRI as Breast Cancer Surveillance: A Feasibility Study.  Breast. 2010 Sep 7. [Epub ahead of print]
  8. Bordeleau L, Pritchard K, Loprinzi C, Ennis M, Jugovic O, Warr D, Haq R, Goodwin P. A randomized crossover clinical trial of venlafaxine and gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010 Nov 8. [Epub ahead of print]
  9. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009) J Natl Cancer Inst, 2011, 103(3):178-231.  
  10. Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA and the Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer, 2011, 117(9):1812-8.

Search for citations for Dr. Bordeleau on PubMed